Zhi Tong Cai Jing·2026-03-04 08:41Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which will enhance the company's product portfolio and competitive strength in the pharmaceutical market [1] Group 1: Product Approval - The company has obtained the drug registration certificate for Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] - Entacapone tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] Group 2: Market Potential - The estimated sales revenue for Entacapone tablets in Chinese public medical institutions is approximately RMB 286 million in 2024 [1] - The approval of Entacapone tablets will further enrich the company's formulation product series, contributing to an increase in overall competitiveness [1]